Press Releases

Press Releases

June 20, 2018
Magenta Therapeutics Announces Pricing of Initial Public Offering

April 9, 2018
Magenta Therapeutics Secures $52 Million in Series C Financing

April 6, 2018
Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors

April 5, 2018
Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

April 3, 2018
Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.

March 8, 2018
Magenta Therapeutics Strengthens Leadership Team with Promotions, New Hires

March 5, 2018
Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates

February 26, 2018
Magenta Therapeutics Presents Clinical and Preclinical Data at ASBMT Conference, Including New Preclinical Results on Microglial Engraftment with MGTA-456 Expanded Cord Blood Stem Cell Product

February 21, 2018
Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer

January 5, 2018
Magenta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018

December 11, 2017
Magenta Therapeutics Presents Preclinical Data from Stem Cell Mobilization and Expansion Programs

December 11, 2017
Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase 2 Clinical Studies

December 9, 2017
Magenta Therapeutics’ Lead Targeted Antibody Drug Conjugate Shows Promising Preclinical Results for Non-Genotoxic Conditioning for Bone Marrow Transplant

December 7, 2017
New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models with Combination of GROβ and Plerixafor

November 1, 2017
Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting

October 26, 2017
Magenta Therapeutics Strengthens Leadership Team

October 24, 2017
Magenta Therapeutics Appoints Alison Lawton, Jeff Albers and Blake Byers to its Board of Directors

September 26, 2017
Fierce Biotech Names Magenta Therapeutics as one of its “Fierce 15” Biotech Companies of 2017

May 18, 2017
Magenta Therapeutics Selected as “Hottest Early Stage Startup” in Healthcare in New England Venture Capital Association’s 2017 NEVY Awards

May 2, 2017
Magenta Therapeutics Advances Stem Cell Transplantation Strategy with $50 Million Series B Financing, Licensing of Clinical-Stage Stem Cell Expansion Program and Strategic Partnership with Be The Match BioTherapies

December 2, 2016
Magenta Therapeutics Cofounder David Scadden Honored at the American Society of Hematology Annual Meeting, as Scientific Founders Present New Stem Cell Biology Data

November 16, 2016
Magenta Therapeutics Announces $48.5M Series A Financing to Transform Stem Cell Transplant for Immune and Blood Diseases